REGN
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN
Article Summary
HOLD- Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is being sued for alleged violations of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated by the U.S.
- Securities and Exchange Commission.
- The lawsuit alleges Regeneron Pharmaceuticals, made false and misleading statements about its Phase III Fianlimab-Libtayo study, which ultimately failed to achieve its primary endpoint in statistically significant manner.
- Shareholders who purchased shares during the class period listed are encouraged to contact the DJS Law Group regarding possible lead plaintiff appointments.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 5.9% | 25% | 35.0 ptsBelow Screener (5.9%) - Weak growth |
| EPS Growth Next 5Y ? | 11.2% | 25% | 35.0 ptsBelow Screener (11.2%) - Modest outlook |
| Target Price Upside ? | 21.9% | 20% | 70.0 ptsGood Upside (21.9%) - Target: $825.00 vs Current: $677.00 |
| Gross Margin % ? | 80.9% | 15% | 100.0 ptsExceptional (80.9%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -17.6% | 15% | 40.0 ptsMild Pullback (-17.6%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About REGN
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
- The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
- It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis.
- It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency.
- Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies.
- It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies.
- The company was incorporated in 1988 and is based in Tarrytown, New York.